Overview

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Status:
Terminated
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and efficacy of short-term A-002 treatment on morbidity and mortality when added to atorvastatin and standard of care in subjects with an acute coronary syndrome (ACS).
Phase:
Phase 3
Details
Lead Sponsor:
Anthera Pharmaceuticals
Treatments:
Varespladib methyl